CombiMatrix said that it had record prenatal microarray volume of 1,126 tests in the fourth quarter.
NanoString CEO Brad Gray said on a conference call that oncology was once a primary driver of new instrument placements.
The firm said that it placed 38 XT-8 analyzers in Q4, bringing the total installed base of the instrument to 540 as of the end of 2014.
The firm is also positioning MassArray as a complementary technology to NGS, and hopes to tap into the LDT and liquid biopsy arenas.
The molecular diagnostics firm offered more than 3.2 million shares of its stock at $2.80 per share as part of the offering.
Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.
Joel Achenbach explores at National Geographic why people find science difficult to believe.
In Science this week: gene linked to expansion of the human neocortex, and more.
The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.